WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
CA2564503C
(en)
|
2004-05-04 |
2015-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of mir-122 in hepatitis c virus infected subjects and cells
|
WO2006107826A2
(en)
|
2005-04-04 |
2006-10-12 |
The Board Of Regents Of The University Of Texas System |
Micro-rna's that regulate muscle cells
|
CA2617581A1
(en)
|
2005-08-01 |
2007-02-08 |
The Ohio State University Research Foundation |
Microrna-based methods for the diagnosis of breast cancer
|
ATE494372T1
(de)
|
2005-08-29 |
2011-01-15 |
Regulus Therapeutics Inc |
Verfahren für mir-122a-modulation
|
ES2523989T3
(es)
|
2005-09-12 |
2014-12-03 |
The Ohio State University Research Foundation |
Composiciones para la terapia de cánceres asociados con BCL2
|
EP1968622B1
(en)
|
2006-01-05 |
2014-08-27 |
The Ohio State University Research Foundation |
Microrna expression abnormalities in pancreatic endocrine and acinar tumors
|
ES2461189T3
(es)
|
2006-01-05 |
2014-05-19 |
The Ohio State University Research Foundation |
Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
|
CN102943108B
(zh)
|
2006-01-05 |
2014-05-21 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
EP2369012A1
(en)
|
2006-03-20 |
2011-09-28 |
The Ohio State University Research Foundation |
Micro-RNA fingerprints during human megakaryocytopoiesis
|
CA3042781C
(en)
|
2006-04-03 |
2021-10-19 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
EA201100813A1
(ru)
*
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
JP5731115B2
(ja)
|
2006-05-05 |
2015-06-10 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
遺伝子発現を調節するための化合物および方法
|
ES2425387T3
(es)
|
2006-07-13 |
2013-10-15 |
The Ohio State University Research Foundation |
Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
|
CA2659364C
(en)
|
2006-08-01 |
2017-08-22 |
Board Of Regents Of The University Of Texas System |
Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
EP2090665A2
(en)
|
2006-10-20 |
2009-08-19 |
Exiqon A/S |
Novel human microRNAs associated with cancer
|
CA2681568C
(en)
|
2006-11-23 |
2019-01-08 |
Querdenker Aps |
Oligonucleotides for modulating target rna activity
|
US8034560B2
(en)
|
2007-01-31 |
2011-10-11 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
|
CA2681406A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
US8288358B2
(en)
|
2007-03-26 |
2012-10-16 |
Newcastle Innovation Ltd. |
Therapeutic targets and molecules
|
CA2685840C
(en)
*
|
2007-04-30 |
2016-12-13 |
The Ohio State University Research Foundation |
Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
|
CN101821390A
(zh)
|
2007-06-14 |
2010-09-01 |
米尔克斯治疗有限责任公司 |
用于调节靶rna活性的寡核苷酸
|
CN101918424A
(zh)
|
2007-06-15 |
2010-12-15 |
俄亥俄州立大学研究基金会 |
用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
|
CN101809169B
(zh)
|
2007-07-31 |
2013-07-17 |
俄亥俄州立大学研究基金会 |
通过靶向dnmt3a和dnmt3b恢复甲基化的方法
|
NZ583024A
(en)
|
2007-07-31 |
2012-04-27 |
Regents The Univeristy Of Texas System Board Of |
An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
|
EP2187896B1
(en)
|
2007-07-31 |
2016-01-13 |
The Board of Regents of The University of Texas System |
Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction
|
ES2627059T3
(es)
|
2007-08-03 |
2017-07-26 |
The Ohio State University Research Foundation |
Regiones ultraconservadas que codifican ARNnc
|
JP5770472B2
(ja)
|
2007-08-22 |
2015-08-26 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation |
ヒト急性白血病におけるepha7及びerkリン酸化の調節解除を誘発するための方法及び組成物
|
AU2013273821B2
(en)
*
|
2007-10-04 |
2016-03-10 |
Roche Innovation Center Copenhagen A/S |
Micromirs
|
ES2463665T3
(es)
|
2007-10-04 |
2014-05-28 |
Stella Aps |
Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
|
AU2008310704B2
(en)
*
|
2007-10-11 |
2014-03-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
|
WO2009055773A2
(en)
|
2007-10-26 |
2009-04-30 |
The Ohio State University Research Foundation |
Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
|
WO2009058907A2
(en)
|
2007-10-29 |
2009-05-07 |
Isis Pharmaceuticals, Inc. |
Targeting micrornas for the treatment of liver cancer
|
WO2009062169A2
(en)
*
|
2007-11-09 |
2009-05-14 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
|
GB0802754D0
(en)
*
|
2008-02-14 |
2008-03-26 |
Inst Superiore Di Sanito |
Antisense RNA targetting CXCR4
|
CA2716343A1
(en)
*
|
2008-02-21 |
2009-08-27 |
The Board Of Regents Of The University Of Texas System |
Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
|
EP2096171A1
(en)
|
2008-02-27 |
2009-09-02 |
Julius-Maximilians-Universität Würzburg |
MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
|
CN102007223B
(zh)
*
|
2008-02-28 |
2014-06-18 |
俄亥俄州立大学研究基金会 |
用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
CA2718520C
(en)
|
2008-03-17 |
2020-01-07 |
The Board Of Regents Of The University Of Texas System |
Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
|
EP2105145A1
(en)
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
EP2281903B1
(en)
|
2008-04-30 |
2017-01-04 |
NEC Corporation |
METHOD FOR EVALUATION OF CANCER BY USING miRNA CANCER MARKER
|
EP2307028B1
(en)
|
2008-06-11 |
2013-10-02 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
|
JP5686730B2
(ja)
*
|
2008-06-16 |
2015-03-18 |
ユニフェルシテイト マーストリヒトUniversiteit Maastricht |
心臓肥大を抑制、遅延、および/または予防するための方法、および医薬組成物
|
CA2728816A1
(en)
|
2008-06-27 |
2009-12-30 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Instit Ute For Biomedical Research |
Prediction of antiviral therapy response
|
ES2541442T3
(es)
|
2008-08-01 |
2015-07-20 |
Roche Innovation Center Copenhagen A/S |
Modulación mediada por microARN de factores estimulantes de colonias
|
EP2191834A1
(en)
*
|
2008-11-26 |
2010-06-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Compositions and methods for treating retrovirus infections
|
JP6091752B2
(ja)
*
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療
|
JP5793423B2
(ja)
|
2008-12-31 |
2015-10-14 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
急性冠症候群の治療のためのLNAApoBアンチセンスオリゴマーの使用
|
EP2393945A4
(en)
|
2009-02-04 |
2013-08-07 |
Univ Texas |
DOUBLE TARGETING OF MIR-208 AND MIR-499 IN THE TREATMENT OF CARDIAC DISORDERS
|
EP2218458A1
(en)
*
|
2009-02-13 |
2010-08-18 |
Fondazione Telethon |
Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
|
US8785414B2
(en)
|
2009-03-31 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
|
EP2421970B1
(en)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
|
EP2432880A1
(en)
|
2009-05-20 |
2012-03-28 |
ETH Zürich |
Targeting micrornas for metabolic disorders
|
WO2010135714A2
(en)
*
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
US20110190372A1
(en)
*
|
2009-08-07 |
2011-08-04 |
New York University |
Compositions and methods for treating inflammatory disorders
|
WO2011022316A1
(en)
*
|
2009-08-20 |
2011-02-24 |
The Regents Of The University Of Colorado, A Body Corporate |
Mirnas dysregulated in triple-negative breast cancer
|
CN102002493B
(zh)
*
|
2009-09-01 |
2013-04-10 |
中国科学院上海生命科学研究院 |
小rna-326制备药物的应用
|
WO2011032100A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
US8975019B2
(en)
*
|
2009-10-19 |
2015-03-10 |
University Of Massachusetts |
Deducing exon connectivity by RNA-templated DNA ligation/sequencing
|
WO2011048125A1
(en)
|
2009-10-20 |
2011-04-28 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
EP2504452A4
(en)
|
2009-11-23 |
2014-06-11 |
Univ Ohio State Res Found |
SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
|
US20120302626A1
(en)
|
2009-12-04 |
2012-11-29 |
Sandeep Dave |
Microrna and use thereof in identification of b cell malignancies
|
US9340782B2
(en)
|
2010-01-20 |
2016-05-17 |
Board Of Regents, The University Of Texas System |
Antimir-451 for the treatment of polycythemias
|
WO2011111715A1
(ja)
*
|
2010-03-09 |
2011-09-15 |
協和発酵キリン株式会社 |
細胞周期を制御する核酸
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
EP2550360B1
(en)
*
|
2010-03-24 |
2017-08-30 |
Mirrx Therapeutics A/s |
Bivalent antisense oligonucleotides
|
AU2011243291A1
(en)
*
|
2010-04-21 |
2012-11-01 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Means and methods for determining risk of cardiovascular disease
|
WO2011134474A1
(en)
*
|
2010-04-30 |
2011-11-03 |
Exiqon A/S |
In situ hybridization method and buffer
|
US20110281933A1
(en)
*
|
2010-05-13 |
2011-11-17 |
Saint Louis University |
Methods and compositions for the management of cardiovascular disease with oligonucleotides
|
FR2960130B1
(fr)
|
2010-05-21 |
2013-11-01 |
Dominique Cingotti |
Agent edulcorant contenant un extrait de stevia rebaudiana bertoni
|
US20130210883A1
(en)
|
2010-05-21 |
2013-08-15 |
Johannes Grillari |
Lipase inhibitors
|
WO2011144761A1
(en)
|
2010-05-21 |
2011-11-24 |
Universität Für Bodenkultur Wien |
Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
|
EP2576785A4
(en)
|
2010-06-04 |
2014-12-24 |
Univ Texas |
REGULATION OF METABOLISM BY MIR-378
|
EP2580328A2
(en)
|
2010-06-11 |
2013-04-17 |
Cellartis AB |
Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
|
JP5099570B2
(ja)
|
2010-07-12 |
2012-12-19 |
国立大学法人鳥取大学 |
siRNA導入による新規hiPSC作製法
|
US8815826B2
(en)
|
2010-07-23 |
2014-08-26 |
Regulus Therapeutics, Inc. |
Targeting microRNAs for the treatment of fibrosis
|
EP2608812B1
(en)
|
2010-08-25 |
2018-08-15 |
The General Hospital Corporation |
Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
|
US20120053227A1
(en)
|
2010-08-27 |
2012-03-01 |
New York University |
miR-33 INHIBITORS AND USES THEREOF
|
WO2012048113A2
(en)
|
2010-10-07 |
2012-04-12 |
The General Hospital Corporation |
Biomarkers of cancer
|
CN102031261B
(zh)
*
|
2010-10-27 |
2015-04-22 |
南京医科大学 |
一种与妊娠期糖尿病相关的血清/血浆miRNA标志物及其应用
|
WO2012065027A2
(en)
*
|
2010-11-11 |
2012-05-18 |
University Of Miami |
Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
|
WO2012063894A1
(ja)
|
2010-11-12 |
2012-05-18 |
国立大学法人愛媛大学 |
マイクロrnaのアンチセンスオリゴヌクレオチドを含む組成物
|
AU2011326032B2
(en)
|
2010-11-12 |
2016-10-06 |
The Ohio State University Research Foundation |
Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012065143A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
BR112013011942A2
(pt)
|
2010-11-15 |
2016-11-01 |
Univ Michigan |
formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
|
CN102041316A
(zh)
*
|
2010-11-30 |
2011-05-04 |
华东师范大学 |
miRNA-219化合物作为脑胶质瘤标志物的应用
|
BR112013012319A2
(pt)
*
|
2010-12-15 |
2019-09-24 |
Miragen Therapeutics |
inibidores de micro rna compreendendo nucleotídeos bloqueados
|
SG191174A1
(en)
|
2010-12-20 |
2013-07-31 |
Agency Science Tech & Res |
Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
CN102174516A
(zh)
*
|
2011-01-20 |
2011-09-07 |
中南大学 |
一种与ebv感染相关的鼻咽癌诊断和治疗的分子靶标及其应用
|
JP2014509852A
(ja)
*
|
2011-03-07 |
2014-04-24 |
ジ・オハイオ・ステート・ユニバーシティ |
マイクロRNA−155(miR−155)により誘導される変異誘発活性は炎症および癌を結び付ける
|
JP2014515024A
(ja)
*
|
2011-04-12 |
2014-06-26 |
ベス イスラエル デアコネス メディカル センター, インコーポレイテッド |
マイクロrna阻害剤および疾患におけるその使用
|
WO2012145374A1
(en)
|
2011-04-19 |
2012-10-26 |
Regulus Therapeutics Inc. |
TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
|
ES2868950T3
(es)
|
2011-04-25 |
2021-10-22 |
Sanofi Sa |
Compuestos de microARN y métodos para modular la actividad de miR-21
|
US9241950B2
(en)
|
2011-04-28 |
2016-01-26 |
New York University |
MiR-33 inhibitors and uses thereof to decrease inflammation
|
US20140127159A1
(en)
|
2011-06-23 |
2014-05-08 |
Stella Aps |
HCV Combination Therapy
|
US20140194491A1
(en)
*
|
2011-06-24 |
2014-07-10 |
Syddansk Universitet |
Modulation of microrna-138 for the treatment of bone loss
|
KR20140058536A
(ko)
|
2011-06-30 |
2014-05-14 |
스텔라 에이피에스 |
Hcv 조합 치료
|
US20140113958A1
(en)
|
2011-06-30 |
2014-04-24 |
Stella Aps |
HCV Combination Therapy
|
CN102908621A
(zh)
*
|
2011-08-02 |
2013-02-06 |
中国科学院上海生命科学研究院 |
miRNAs作为调节胰岛素敏感性的靶标的新用途
|
WO2013030362A1
(en)
*
|
2011-08-31 |
2013-03-07 |
Universität Zürich Prorektorat Mnw |
Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
|
CN102978278B
(zh)
*
|
2011-09-07 |
2016-09-28 |
中国科学院动物研究所 |
内源性的非编码小RNAs及其应用
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
EP2763703B1
(en)
|
2011-10-06 |
2018-02-14 |
Miragen Therapeutics, Inc. |
Control of whole body energy homeostasis by microrna regulation
|
US10184151B2
(en)
*
|
2011-10-11 |
2019-01-22 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
GB201117482D0
(en)
*
|
2011-10-11 |
2011-11-23 |
Univ Dundee |
Targetiing of miRNA precursors
|
JP2014530612A
(ja)
|
2011-10-14 |
2014-11-20 |
ジ・オハイオ・ステート・ユニバーシティ |
卵巣がんに関する方法および材料
|
CA2853328A1
(en)
|
2011-11-07 |
2013-05-16 |
Stella Aps |
Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
CN104619353A
(zh)
*
|
2011-12-13 |
2015-05-13 |
俄亥俄州国家创新基金会 |
与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
|
EP2816114A3
(en)
*
|
2011-12-15 |
2015-02-25 |
Oncostamen S.r.l. |
MicroRNAs and uses thereof
|
US9447471B2
(en)
*
|
2011-12-29 |
2016-09-20 |
Quest Diagnostics Investments Incorporated |
Microrna profiling for diagnosis of dysplastic nevi and melanoma
|
JP2015511121A
(ja)
|
2012-01-20 |
2015-04-16 |
ジ・オハイオ・ステート・ユニバーシティ |
浸潤性および予後に関する乳がんバイオマーカーシグネチャー
|
US8969317B2
(en)
*
|
2012-04-25 |
2015-03-03 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
US9334498B2
(en)
|
2012-05-10 |
2016-05-10 |
Uab Research Foundation |
Methods and compositions for modulating MIR-204 activity
|
AU2013262649A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating smn gene family expression
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
AP2014008100A0
(en)
|
2012-05-16 |
2014-12-31 |
Gen Hospital Corp |
Compositions and methods for modulating hemoglobingene family expression
|
EP3511416A1
(en)
|
2012-05-16 |
2019-07-17 |
Translate Bio MA, Inc. |
Compositions and methods for modulating gene expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
WO2013190091A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Ruprecht-Karls-Universität Heidelberg |
CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
|
US9163235B2
(en)
*
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
WO2013192576A2
(en)
|
2012-06-21 |
2013-12-27 |
Miragen Therapeutics |
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
EP2885008B1
(en)
|
2012-08-15 |
2018-11-07 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
WO2014030602A1
(ja)
|
2012-08-20 |
2014-02-27 |
独立行政法人国立がん研究センター |
癌治療剤
|
WO2014043544A1
(en)
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
CN109793897B
(zh)
*
|
2012-10-31 |
2022-02-01 |
洛克菲勒大学 |
结肠癌的治疗和诊断
|
CN104837996A
(zh)
|
2012-11-15 |
2015-08-12 |
罗氏创新中心哥本哈根有限公司 |
抗apob反义缀合物化合物
|
US20150299702A1
(en)
*
|
2012-11-30 |
2015-10-22 |
Aarhus Universitet |
Circular rna for inhibition of microrna
|
CA2893801A1
(en)
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
WO2014145356A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
US9752143B2
(en)
|
2013-03-15 |
2017-09-05 |
MiRagen Therapeutics, Inc. |
Locked nucleic acid inhibitor of miR-145 and uses thereof
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
WO2014179446A2
(en)
|
2013-05-01 |
2014-11-06 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-122
|
AU2014259953B2
(en)
|
2013-05-01 |
2020-07-02 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
CN103293318B
(zh)
*
|
2013-05-22 |
2014-10-29 |
吉林大学 |
利用地高辛标记EDC交联桥连法检测miRNAs方法
|
WO2014201301A1
(en)
*
|
2013-06-12 |
2014-12-18 |
New York University |
Anti-mir-27b and anti-mir-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
|
WO2014201314A1
(en)
|
2013-06-14 |
2014-12-18 |
Joslin Diabetes Center, Inc. |
Microrna and uses in brown fat differentiation
|
EP3591054A1
(en)
|
2013-06-27 |
2020-01-08 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting pcsk9
|
EP3024933A4
(en)
*
|
2013-07-24 |
2017-03-15 |
The General Hospital Corporation |
Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels
|
JP6443889B2
(ja)
*
|
2013-08-08 |
2018-12-26 |
国立大学法人大阪大学 |
尿路上皮癌の診断または治療剤
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
US9458458B2
(en)
|
2013-11-11 |
2016-10-04 |
Emory University |
Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
|
EP3105327A4
(en)
*
|
2014-02-12 |
2017-10-18 |
Thomas Jefferson University |
Compositions and methods of using microrna inhibitors
|
AU2015259362B2
(en)
|
2014-05-12 |
2018-02-15 |
The Johns Hopkins University |
Engineering synthetic brain penetrating gene vectors
|
US10335500B2
(en)
|
2014-05-12 |
2019-07-02 |
The Johns Hopkins University |
Highly stable biodegradable gene vector platforms for overcoming biological barriers
|
EP3760208B1
(en)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
EP3177722A4
(en)
*
|
2014-07-31 |
2018-01-17 |
Agency For Science, Technology And Research |
Modified antimir-138 oligonucleotides
|
KR20170033439A
(ko)
|
2014-08-07 |
2017-03-24 |
레굴루스 테라퓨틱스 인크 |
대사 장애에 대한 마이크로rna의 표적화
|
WO2016042561A2
(en)
|
2014-09-21 |
2016-03-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Downregulating mir-132 for the treatment of lipid related disorders
|
CN104306988B
(zh)
*
|
2014-09-25 |
2017-02-15 |
中国医学科学院基础医学研究所 |
miR‑431在制备治疗肌肉疾病的药物中的用途
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
JP2017534281A
(ja)
*
|
2014-11-10 |
2017-11-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
潰瘍性大腸炎に特異的な診断および予後予測のバイオマーカーとしてのmir−214ならびに潰瘍性大腸炎治療のためのmir−214阻害剤
|
JP6863891B2
(ja)
*
|
2014-11-14 |
2021-04-21 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
調節性ポリヌクレオチド
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Preparations and methods for the treatment of amyotrophic lateral sclerosis
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
CN107636003A
(zh)
|
2015-01-20 |
2018-01-26 |
米拉根医疗股份有限公司 |
miR‑92抑制剂及其用途
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
INTERACTOME RNA OF COMPLEX REPRESSIVE POLYCOMB 1 (PRC1)
|
EP3283502A4
(en)
|
2015-04-07 |
2019-04-03 |
The General Hospital Corporation |
METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME
|
CN108138180A
(zh)
*
|
2015-06-05 |
2018-06-08 |
米拉根医疗股份有限公司 |
用于治疗皮肤t细胞淋巴瘤(ctcl)的mir-155抑制剂
|
CA2986913A1
(en)
*
|
2015-06-05 |
2016-12-08 |
MiRagen Therapeutics, Inc. |
Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
ES2965461T3
(es)
|
2015-08-03 |
2024-04-15 |
Biokine Therapeutics Ltd |
Inhibidor de CXCR4 para el tratamiento del cáncer
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
AU2016326548A1
(en)
*
|
2015-09-22 |
2018-03-29 |
MiRagen Therapeutics, Inc. |
miR-19 modulators and uses thereof
|
JP6893505B2
(ja)
|
2015-10-02 |
2021-06-23 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲーション方法
|
WO2017062659A1
(en)
*
|
2015-10-06 |
2017-04-13 |
University Of Virginia Patent Foundation |
Compositions and methods for treating diabetic retinopathy
|
JP6666002B2
(ja)
|
2015-10-07 |
2020-03-13 |
国立大学法人京都大学 |
Tdp−43プロテノパシーの予防又は治療用組成物
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
CN107012199A
(zh)
*
|
2016-01-28 |
2017-08-04 |
上海市东方医院 |
一种在血浆和血清中检测miRNA的方法
|
CA3054284A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
EP3430021A1
(en)
|
2016-03-18 |
2019-01-23 |
Roche Innovation Center Copenhagen A/S |
Acyl-protected l-lna-guanosine monomers
|
DK3455232T3
(da)
|
2016-05-12 |
2020-07-06 |
Roche Innovation Ct Copenhagen As |
Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
US11015196B2
(en)
|
2016-05-20 |
2021-05-25 |
The General Hospital Corporation |
Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
|
CN109312403B
(zh)
|
2016-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
体外肾毒性筛选测定法
|
CN109328236B
(zh)
|
2016-06-17 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
体外肾毒性筛选测定法
|
EP3481430A4
(en)
|
2016-07-11 |
2020-04-01 |
Translate Bio Ma, Inc. |
NUCLEIC ACID CONJUGATES AND USES THEREOF
|
EP3484526A4
(en)
*
|
2016-07-18 |
2020-04-15 |
Jaan Biotherapeutics, LLC |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE
|
EP3494219A1
(en)
|
2016-08-03 |
2019-06-12 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
WO2018080658A1
(en)
*
|
2016-10-27 |
2018-05-03 |
Aalborg University |
Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
|
EP3532638A4
(en)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
|
AU2017353907B2
(en)
|
2016-11-01 |
2023-11-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
EP3558328A4
(en)
|
2016-12-22 |
2020-08-26 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS OF REPROGRAMMING SOMATIC CELLS INTO INDUCED VASCULAR CELLS
|
US11591362B2
(en)
|
2017-03-29 |
2023-02-28 |
Roche Innovation Center Copenhagen A/S |
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
|
US11542294B2
(en)
|
2017-03-29 |
2023-01-03 |
Roche Innovation Center Copenhagen A/S |
Rapid unylinker cleavage
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
AU2018261790A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
EP3645544B1
(en)
|
2017-06-28 |
2023-05-10 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling&oxidation method
|
WO2019073018A1
(en)
|
2017-10-13 |
2019-04-18 |
Roche Innovation Center Copenhagen A/S |
METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
EP3703669A4
(en)
|
2017-11-01 |
2021-11-10 |
Dana-Farber Cancer Institute, Inc. |
CANCER TREATMENT METHODS
|
CN108272815B
(zh)
*
|
2017-12-06 |
2020-09-11 |
南方医科大学深圳医院 |
EB病毒miR-BART10-5p抑制剂的应用
|
CN108220381A
(zh)
*
|
2017-12-07 |
2018-06-29 |
国家卫生计生委科学技术研究所 |
试剂在制备药物中的用途以及筛选药物的方法
|
MX2020006430A
(es)
|
2017-12-22 |
2020-09-17 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
|
TW201934750A
(zh)
|
2017-12-22 |
2019-09-01 |
丹麥商羅氏創新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
|
WO2019122277A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Novel thiophosphoramidites
|
CA3093844A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Beth Israel Deaconess Medical Center |
Micro-rna and obesity
|
CN108220427B
(zh)
*
|
2018-03-20 |
2021-09-28 |
南京大学 |
一种用于鉴别诊断BHD综合征与原发性自发性气胸的血浆microRNA标记物及应用
|
EP3793685A1
(en)
*
|
2018-05-18 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Pharmaceutical compositions for treatment of microrna related diseases
|
US11679100B2
(en)
|
2018-05-30 |
2023-06-20 |
The Regents Of The University Of California |
Methods of enhancing immunity
|
CN110777199B
(zh)
*
|
2018-07-24 |
2023-11-14 |
长庚医疗财团法人高雄长庚纪念医院 |
干癣性关节炎的诊断及治疗及其相应的试剂盒
|
CN112236439A
(zh)
|
2018-07-31 |
2021-01-15 |
罗氏创新中心哥本哈根有限公司 |
包含三硫代磷酸酯核苷间键的寡核苷酸
|
CA3105705A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
CA3110661A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
CN110468202A
(zh)
*
|
2019-01-18 |
2019-11-19 |
宁夏医科大学 |
一种靶向TIGIT的miR-206作为肝癌诊断和治疗新型分子的用途
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
JP2022521512A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規ホスホルアミダイト
|
CA3130431A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
CN113905744A
(zh)
|
2019-05-31 |
2022-01-07 |
阿利戈斯治疗公司 |
经修饰的间隙子寡核苷酸及其使用方法
|
BR112021026365A2
(pt)
|
2019-06-26 |
2022-05-10 |
Biorchestra Co Ltd |
Nanopartículas micelares e usos das mesmas
|
CN110548041A
(zh)
*
|
2019-08-30 |
2019-12-10 |
中国医科大学附属盛京医院 |
LNA-anti-miR-150在制备预防或治疗肾脏纤维化药物中的用途
|
CN111057790B
(zh)
*
|
2019-12-11 |
2022-08-30 |
石河子大学 |
miRNA在制备用于检测KSHV潜伏感染的试剂盒中的用途
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd73エクソン7スプライシングを調節するためのオリゴヌクレオチド
|
EP4129338A4
(en)
*
|
2020-03-02 |
2024-04-10 |
Mitsubishi Tanabe Pharma Corp |
PREVENTION OR TREATMENT OF ANEURYSMS WITH MIR-33B INHIBITOR
|
KR102555878B1
(ko)
*
|
2020-04-23 |
2023-07-17 |
주식회사 바이오오케스트라 |
하향조절된 mirna의 진단 및 치료를 위한 용도
|
WO2021251526A1
(ko)
*
|
2020-06-11 |
2021-12-16 |
주식회사 프로스테믹스 |
신규한 mirna 유사체 및 이의 용도
|
CN112301130B
(zh)
*
|
2020-11-12 |
2021-11-30 |
苏州京脉生物科技有限公司 |
一种肺癌早期检测的标志物、试剂盒及方法
|
AU2022219031A1
(en)
|
2021-02-12 |
2023-09-07 |
Merand Pharmaceuticals, Inc. |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
WO2022254021A1
(en)
|
2021-06-04 |
2022-12-08 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
WO2022260162A1
(ja)
*
|
2021-06-11 |
2022-12-15 |
国立大学法人京都大学 |
Nashの予防及び/又は治療剤
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
KR102329524B1
(ko)
*
|
2021-08-06 |
2021-11-23 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
WO2023013818A1
(ko)
*
|
2021-08-06 |
2023-02-09 |
주식회사 네오나 |
변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
|
CA3228833A1
(en)
|
2021-08-19 |
2023-02-23 |
Neumirna Therapeutics Aps |
Antisense oligonucleotides targeting adenosine kinase
|
CN118043462A
(zh)
*
|
2021-10-08 |
2024-05-14 |
莱古路斯治疗法股份有限公司 |
用于避免脱靶效应的方法和组合物
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|